Management of nevi in transplant patients

Dermatologic Therapy

Volumn 18, Issue 1, 2005, Pages 34-43

  Baron, Jennifer ^a   Krol, Alfons ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Atypical nevi; Immunosuppression; Melanocytic nevi; Melanoma; Organ transplant recipients; Skin cancer

Indexed keywords

ANTINEOPLASTIC AGENT; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; TACROLIMUS;

ALLOGRAFT; CANCER LOCALIZATION; CANCER SCREENING; CANCER SURGERY; CLINICAL EXAMINATION; CONFOCAL LASER MICROSCOPY; CONSULTATION; EPILUMINESCENCE MICROSCOPY; GENETIC SCREENING; GRAFT REJECTION; HUMAN; IMMUNOCOMPETENCE; IMMUNOSUPPRESSIVE TREATMENT; MELANOCYTIC NEVUS; MELANOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; ORGAN TRANSPLANTATION; PATIENT COMPLIANCE; PATIENT EDUCATION; PHYSICAL EXAMINATION; PREOPERATIVE EVALUATION; RAMAN SPECTROMETRY; REVIEW; RISK FACTOR; SELF EXAMINATION; SKIN CANCER; SPECTROSCOPY; SUN EXPOSURE; SURVIVAL RATE; ULTRASOUND;

CHILD; HUMANS; IMMUNOCOMPETENCE; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; MELANOMA; NEVUS; RISK FACTORS; SKIN NEOPLASMS; TRANSPLANTATION;

EID: 18844388682     PISSN: 13960296     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1529-8019.2005.05005.x     Document Type: Review

References (56)

1. Greene MH, Young TI, Clark WH. Malignant melanoma in renal transplant recipients. Lancet 1981: 1: 1196-1199.
2. Penn I. De novo malignancy in pediatric organ transplant recipients. J Ped Surg 1994: 29: 221-228.
3. Penn I. De novo malignancy in pediatric organ transplant recipients. Ped Transplant 1998: 2: 56-63.
4. Jensen P, Hansen S, Moller B et al. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. JAAD 1999: 40: 177-186.
5. Ramsay HM, Fryer AA, Hawley CM et al. Nonmelanoma skin cancer risk in the Queensland renal transplant population. BJD 2002: 147: 950-956.
6. Ulrich C, Christophers E, Sterry W et al. Hauterkrankungen bei organ transplantierten. Patienten 2002: 53: 524-533.
7. Penn I. Malignant melanoma in organ allograft recipients. Clin Transplant 1996: 61: 274-278.
8. Bhatia S, Ramsay NK, Steinbuch M et al. Malignant neoplasms following bone marrow transplantation. Blood 1996: 87: 3633-3639.
9. Bouwes Bavnick JN, Hardie DR, Green A et al. The risk of skin cancer in renal transplant recipients in Queensland, Australia. A follow-up study. Transplant 1996: 61: 715-721.
10. Thiel G, Bock A, Spondlin M et al. Long-term benefits and risks of cyclosporine A (sandimmun) - an analysis at 10 years. Transplant Proc 1994: 26: 2493-2498.
11. Ramsay HM, Fryer AA, Reece S et al. Clinical risk factors associated with nonmelanoma skin cancer in renal transplant recipients. Am J Kid Dis 2000: 36: 167-176.
12. Swetter SM. Dermatological perspectives of malignant melanoma. Surg Clin N Amer 2003: 83.
13. Sheil AG. Skin cancer in renal transplant recipients. Transplant Sci 1994: 4: 42-45.
14. Glover MT, Niranjan JT, Kwan JT, Leigh IM. Nonmelanoma skin cancer in renal transplant recipients: the extent of the problem and a strategy for management. Br J Plast Surg 1994: 47: 86-89.
15. Frezza EE, Fung JJ, van Thiel DH. Nonlymphoid cancer after liver transplantation. Hepatogastroenterology 1997: 44: 1172-1181.
16. Ducloux D, Carron PL, Rebibou JM et al. CD4 lymphocytopenia as a risk factor for skin cancers in renal transplant recipients. Transplantation 1998: 65: 1270-1272.
17. Caforio AL, Fortina AB, Piaserico S et al. Skin cancer in heart transplant recipients: risk factor analysis and relevance of immunosuppressive therapy. Circulation 2000: 102: 111222-111227.
18. Grob JJ, Gouvernet J, Aymar D et al. Count of benign melanocytic nevi as a major indicator of risk for nonfamiliar nodular and superficial spreading melanoma. Cancer 1990: 60: 387-395.
19. Youl P, Aitken J, Hayward N et al. Melanoma in adolescents: a case-control study of risk factors in Queensland. Australia Int J Cancer 2002: 98: 92-98.
20. Greene A, Swerdlow AJ. Epidemiology of melanocytic nevi. Epidemiol Rev 1989: 11: 204-221.
21. Garbe C, Buttner P, Weis J et al. Risk factors for developing cutaneous melanoma and criteria for identifying persons at risk: multicenter case-control study of the central malignant melanoma registry of the German Dermatological Society. J Invest Dermatol 1994: 102: 695-699.
22. Bouwes Bavinck JN, Crijns M, Vermeer BJ et al. Chronic sun exposure and age are inversely associated with nevi in adult renal transplant recipients. J Invest Dermatol 1996: 106: 1036-1041.
23. Rivers JK. Melanoma. Lancet 1996: 347: 803-807.
24. Wang SQ, Setlow R, Berwick M. Ultraviolet A and melanoma: a review. J Am Acad Dermatol 2001: 44: 837-846.
25. Swerdlow AJ, Weinstock MA. Do tanning lamps cause melanoma? An epidemiologic assessment. JAAD 1998: 38: 89-98.
26. Clark WH, Reimer RR, Greene M et al. Origin of familial malignant melanomas from heritable melanocytic lesions. "The B-K mole syndrome". Arch Dermatol 1978: 114: 732-738.
27. Kennedy C, Bajdik CD, Willemze R et al. The influence of painful sunburns and lifetime sun exposure on the risk of actinic keratoses, seborrheic warts, melanocytic nevi, atypical nevi, and skin cancer. J Invest Derm 2003: 120: 1087-1093.
28. Jhappan C, Noonan FP, Merlino G. Ultraviolet radiation and cutaneous malignant melanoma. Oncogene 2003: 22: 3099-3112.
29. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Eng J Med 2003: 348: 1681-1691.
30. Bower CP, Lear JR, Bygrave S et al. Basal cell carcinoma and risk of subsequent malignancies: a cancer registry-based study in southwest England. JAAD 2000: 42: 988-991.
31. Bittencourt FV, Marghoob AA, Kopf AW et al. Large congenital melanocytic nevi and the risk for development of malignant melanoma and neurocutaneous melanocytosis. Pediatrics 2000: 106: 736-741.
32. Gosain AK, Santoro TD, Larson DL et al. Giant congenital nevi: a 20-year experience and an algorithm for their management. Plast Recon Surg 2001: 108: 622-631.
33. Baader W, Kropp R, Tapper D. Congenital malignant melanoma. Plast Reconstr Surg 1992: 90: 53-56.
34. Tucker MA, Crutcher WA, Hartge P, Sagebiel RW. Familial and cutaneous features of dysplastic nevi: a case-control study. J Am Acad Dermatol 1993: 28: 558-564.
35. Gulec AT, Seckin D, Saray Y et al. Number of acquired melanocytic nevi in renal transplant recipients as a risk factor for melanoma. Transplant Proc 2002: 34: 2136-2138.
36. Barker JN, MacDonald DM. Eruptive dysplastic naevi following renal transplantation. Clin Exp Dermatol 1988: 13: 123-125.
37. McGregor JM, Barker JN, MacDonald DM. The development of excess numbers of melanocytic naevi in an immunosuppressed identical twin. Clin Exp Dermatol 1991: 16: 131-132.
38. Andreani V, Richard MA, Blaise D et al. Naevi in allogeneic bone marrow transplantation recipients: the effect of graft-versus-host disease on naevi. Br J Dermatol 2002: 147: 433-441.
39. Carli P, De Giorgi V, Palli D et al. Dermatologist detection and skin self-examination are associated with thinner melanomas. Arch Dermatol 2003: 139: 607-612.
40. Brady MS, Oliveria SA, Christos PJ et al. Patterns of detection in patients with cutaneous melanoma: implications for secondary prevention. Cancer 2000: 89: 342-347.
41. Robinson JK, Nickoloff BJ. Digital epiluminescence microscopy monitoring of high-risk patients. Arch Dermatol 2004: 140: 49-56.
42. Kanzler MH, Mraz-Gernhard S. Primary cutaneous malignant melanoma and its precursor lesions: diagnostic and therapeutic overview. J Am Acad Dermatol 2001: 45: 260-276.
43. Pehamberger H, Binder M, Steiner A, Wolff K. In vivo epiluminescence microscopy: improvement of early diagnosis of melanoma. J Invest Dermatol 1993: 100: 356S-62S.
44. Binder M, Puespoeck-Schwartz M, Steiner A et al. Epiluminescence microscopy of small pigmented skin lesions: short-term formal training improves diagnostic performance of dermatologists. JAAD 1997: 36: 197-202.
45. Marghoob AA, Swindle LD, Moricz CZ et al. Instruments and new technologies for the in vivo diagnosis of melanoma. J Am Acad Dermatol 2003: 49: 777-797.
46. Gniadecka M, Philipsen PA, Sigurdsson S et al. Melanoma diagnosis by raman spectroscopy and neural networks: structure alterations in proteins and lipids in intact cancer tissue. J Invest Dermatol 2004: 122: 443-449.
47. Bataille V, Sasieni P, Cuzick J et al. Risk of ocular melanoma in relation to cutaneous and iris naevi. Int J Cancer 1995: 60: 622-626.
48. Naeyaert JM, Brochez L, Dysplastic nevi. N Engl J Med 2003: 349: 2233-2240.
49. Kefford RF, Newton Bishop JA, Bergman W et al. Counseling and DNA testing for individuals perceived to be genetically predisposed to melanoma: a consensus statement of the Melanoma Genetics Consortium. J Clin Oncol 1999: 17: 3245-3251.
50. Bergman W, Van Voorst Vader PC, Ruiter DJ. Dysplastic naevi and the risk of melanoma: a guideline for patient care. Ned Tijdschr Geneskd 1997: 141: 2010-2014.
51. NIH Consensus Conference: diagnosis and treatment of early melanoma. JAMA 1992: 268: 1314-1319.
52. Seukeran DC, Newstead CG, Cunliffe WJ. The compliance of renal transplant recipients with advice about sun protection measures. Br J Dermatol 1998: 138: 301-303.
53. Gallagher RP, Rivers JK, Lee TK et al. Broad-spectrum sunscreen use and the development of new nevi in white children. A randomized controlled trial. J Am Med Assoc 2000: 283: 2955-2960.
54. Balch CM, Murad TM, Soong SJ et al. A multifactorial analysis of melanoma: prognostic histopathological features comparing Clark's and Breslow staging methods. Ann Surg 1978: 188: 732.
55. MacKie RM, Reid R, Junor B. Fatal melanoma transferred in a donated kidney 16 years after melanoma surgery. N Engl J Med 2003: 348: 567-568.
56. Moloney FJ, Kelly PO, Kay W et al. Maintenance versus reduction of immunosuppression in renal transplant recipients with aggressive squamous cell carcinoma. Dermatol Surg 2004: 30: 674-678.